We are international
Donate
• health professionals TEXT SIZE   
Bringing the Experts to You



XIIth International Myeloma Workshop, Day 4, March 1, 2009

  • 08:15-10:15 Pro and Con Session
  • 10:30-12:30 Phase II Studies
  • 13:30-15:00 Plenary Session
  • 15:30-17:30 Future Perspectives/Closing Ceremony
Complete Program Listing

2009 IMW Sunday Sessions

Phase II Studies
Early Combination Studies - "New Combination Approaches for MM"
XIIth International Myeloma Workshop in Washington, DC
Antonio Palumbo, M.D.
Ospedale San Giovanni Battista
Torino, Italia

New Proteasome Inhibitors
XIIth International Myeloma Workshop in Washington, DC
Robert Orlowski, M.D.
MD Anderson Cancer Center
Houston, Texas

Novel Bone Targeting Agents in Myeloma
XIIth International Myeloma Workshop in Washington, DC
Noopur Raje, M.D.
Massachusetts General Hospital Cancer Center
Center for Multiple Myeloma
Boston, Massachusetts

New Imids
XIIth International Myeloma Workshop in Washington, DC
Martha Lacy, M.D.
Mayo Clinic
Rochester, Minnesota

Plenary Session
Lenalidomide Inhibits the Multiple Myeloma Cell-Survival Factor IRF4/MUM1
XIIth International Myeloma Workshop in Washington, DC
Antonia Lopez-Girona, M.D.
Celgene Corporation

Centrosomal Clustering – a Novel Therapeutic Target for Multiple Myeloma
XIIth International Myeloma Workshop in Washington, DC
Marc Raab, M.D.
Dana-Farber Cancer Institute
Boston, Massachusetts

Whole Body MRI in Asymptomatic Plasma Cell Disease
XIIth International Myeloma Workshop in Washington, DC
Jens Hillengass, M.D.
University of Heidelberg
Heidelberg, Germany

Superiority of VTD Over TD Incorporated Into ASCT for Newly Diagnosed MM
XIIth International Myeloma Workshop in Washington, DC
Michele Cavo, M.D.
Istituto "Seragnoli"
Bologna, Italy